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Biliary atresia (BA) is a rare disease of unknown etiology and unpredictable outcome, even when there has been
timely diagnosis and exemplary surgery. It has been the commonest indication for liver transplantation during
childhood for the past 20 years. Hence much clinical and basic research has been directed at elucidating the origin
and pathology of BA. This review summarizes the current clinical variations of BA in humans, its occasional
appearance in animals and its various manifestations in the laboratory as an experimental model.
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There are few diseases where so much is known yet so
little understood than the condition of biliary atresia
(BA). Nonetheless, as our current strategy (Kasai
portoenterostomy (KPE) and liver transplantation where
necessary) for dealing with BA is relatively successful
and about 80-90% of currently affected infants will sur-
vive to adolescence and adulthood-does it matter that
the cause in most cases is still obscure? In most prob-
ably not, although there is a still considerable risk of
significant morbidity related to cirrhosis in those who
have had Kasai portoenterostomy alone. About half of
even biochemically normal adolescent survivors will
have histological cirrhosis [1] and have the potential
for decompensation, portal hypertension and even ma-
lignancy [2]. Furthermore, survivors with successfully
transplanted organs still need to remain pharmacologic-
ally immunosuppressed and therefore have an increased
risk of infection and again malignancy in the form of
post-transplant lymphoproliferative disorders.
The key question that this review aims to address is
what is biliary atresia and what may cause this rare
disease? Increasingly it is evident that BA is not a single
entity with a single aetiology but rather appears to be a
phenotype characterized by an obliterated (or absent) bil-
iary tree presenting in the first few weeks after birth [3].* Correspondence: petersen.claus@mh-hannover.de
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Biliary atresia in the clinic
Although most older textbooks usually talk in terms of
only two variants, embryonic and perinatal, this is far
too simplistic and it also assumes that we know a lot
more about when the disease starts than we actually do
[4]. We prefer to use more verifiably descriptive names
with less assumption on cause. Thus, there are probably
at least four clinical variants which can be defined
(Figure 1).
Biliary atresia and other congenital malformations
Firstly there are those infants with BA who have other
congenital anomalies. These can be further sub-divided
into three groups. Firstly there are those who have
elements of the Biliary Atresia Splenic Malformation
(BASM) syndrome [5,6]. These might include splenic
malformation (usually polysplenia, but also asplenia and
double spleen), disorders of visceral symmetry (e.g. situs
inversus and malrotation), malformations of the intra-
abdominal veins (e.g. absent inferior vena cava, preduo-
denal portal vein) and cardiac anomalies. These infants
are usually girls, and some seem to come from an abnor-
mal intrauterine environment (e.g. maternal diabetes,
maternal thyrotoxicosis). It is almost certain that their
bile duct pathology occurs at the same time as theired Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Patterns of Clinical Biliary Atresia.
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onic phase of organ development, perhaps at 5-6 weeks
of gestation) and therefore at the time that the hepatic
diverticulum is pushing into the mesenchyme of the
prehepatic septum transversum. This is well before any
intrahepatic duct system has formed (7-10 weeks) and at
operation concurs with the observation that the extrahe-
patic biliary tree is often atrophic with little inflamma-
tion and there is usually absence of the common bile
duct. Surprisingly, given this timeline the liver paren-
chyma at the time of birth is actually normal [7] and
there is no difference in their birth weight or gestational
age compared to those with isolated BA [8]. There are
also clear racial differences in that this type is infrequent
in the high incidence areas of the world for BA (e.g.
China, Japan, Korea). Variation in BASM incidence can
also be shown in multiethnic populations such as that of
England and Wales [8]. It is this group which seems
likely to have a clear genetic basis for their spectrum of
anomalies (pace maternal diabetes). So of the range of
possible bile duct development genes (see later); CFC-1
mutations have been have identified in 50% of a French
series of infants with BASM [9]. This gene, present at Ch
2q 21.1, encodes for CRYPTIC protein and mutations
have been related to heterotaxy syndromes (i.e. rando-
mised situs) and cardiac anomalies such as transposition
of the great vessels/ double outlet right ventricle [10].
There is a second group of infants, also with BA,
who have other features of other distinct syndromes.
The example for this is the so-called cat-eye syndro-
me (coloboma, ano-rectal atresia etc.) and in these
chromosomal aneuploidy (Ch 22) has been shown [11].
Finally, some infants with BA have non-syndromic
congenital anomalies such as oesophageal atresia, jejunal
atresia, ano-rectal atresia etc. but none of the peculiaranomalies listed above and for which we have no con-
vincing genetic explanation.
Cystic biliary atresia
The extrahepatic component of BA is usually characte-
rised by atrophy or absence (particularly in BASM) or by
inflammatory obliteration of an intact tree. However, in
about 10% of cases, cyst formation (bile or mucus) can
occur, and may lead to diagnostic confusion with early
obstructed cystic choledochal malformation.
Cholangiography at surgery invariably shows that the
intrahepatic ducts are grossly abnormal with irregularity
and pruning if there is preservation of a tree-like pattern
or a cloud-like appearance caused by multiple intercon-
nections of filamentous intrahepatic biliary ductules.
Such infants belong within the BA spectrum family and
should be termed cystic biliary atresia (CBA) [12]. These
don’t seem to have any racial, genetic or epidemiological
peculiarities but what is clear is that they are observable
on antenatal ultrasound scanning–if looked for. In our
experience about half are detectable–usually the large
ones–and from at least 18-20 weeks gestation [13]. They
also have a better outcome following surgery, probably
because of better quality of luminal continuity with
those intrahepatic ducts.
Isolated biliary atresia
This is the largest clinical grouping and epidemiologi-
cally there is wide geographical (and presumed racial)
variation across the world from about 1 in 5000 births in
Taiwan to about 1 in 18,000 in Northern Europe with no
overt seasonal variation and an equal gender split
[8,14-16].
So what do we know of their aetiology? The initial hy-
pothesis was that these infants also had a developmental
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later than the syndromic groups as no other system
appeared abnormal and perhaps at one of the key stages
in biliary development–the juxtaposition of the intrahe-
patic and extrahepatic bile ducts. Both elements have
different origins, develop along separate lines from
different structures and biliary continuity is only
established by 10-12 weeks gestation. Tan et al. com-
pared the appearance of serial sections at the level of the
porta hepatis in normal fetuses at this gestation with the
histological appearance of the porta of infants with
established isolated BA [17]. They were remarkably simi-
lar showing multiple biliary ductules around branches of
the portal vein undergoing selection, deletion and then
morphing into the larger fully-formed ducts by 13-14
weeks. So, the hypothesis suggests that even isolated BA
might be a form of 1st trimester arrested development–
for whatever reason.
The alternate hypothesis is that such infants once
had a completely formed intact biliary tree but that
obliteration occurs as a secondary, indeed perinatal,
phenomenon [18,19]. The clinical evidence supporting a
patent bile duct system and then obliteration is difficult
to obtain. Anecdotal reports of an initial “neonatal hepa-
titis” picture on investigation but evolving into biliary
atresia later have been suggested. Postnatal biliary oblit-
eration can certainly happen and we previously de-
scribed 3 infants who became jaundiced secondary to
perinatal events (proximity surgery and probable healed
bile duct perforations). Their extrahepatic bile ducts
were completely obliterated although they retained a
normal intrahepatic biliary tree which had dilated by the
time of definitive surgery [20].
Amniotic fluid has been assayed for the hepatic-
exclusive enzyme γ-glutamyl transpeptidase in one large
screening study. The lowest values were found in 3 in-
fants who ultimately proved to have BA which clearly
implied a prenatal onset and absence of bile from the
fetal gastrointestinal tract [21]. The level of bile acids in
the Guthrie blood spots (taken in first few days of life)
has also been measured [22] and showed that 47 (77%)
of 61 infants who later proved to have BA had elevated
total bile acids (>97th percentile, 33 μmol/L) with no
difference if the blood had been taken at <7 days or
>10 days. This suggests that cholestasis is already obvi-
ous (if looked for) during the first post-natal week in at
least three-quarters of those who prove to have isolated
BA. A similar North American study of split bilirubin
levels in 31 infants obtained when they were < 48 hours
old and who later turned out to have BA also showed
levels distinctly higher than controls [23], again implying
established biliary pathology at the time of birth.
Our last, and perhaps most controversial clinical vari-
ant has been that of viral-associated BA–which somemight say is simply the latter group plus a culprit caught
in the act. The role of viruses in the animal model
(whether as instigators or genuine pathogens) will be
outlined in detail later but clinically this entity has been
the subject of much debate since the 1980s and 90s. Ini-
tially, work focused on serology of REOvirus type 3 [24],
but a more sophisticated search evolved for actual viral
footprints within the liver and specifically for group C
rotavirus (positive in 50% of BA infants) [25] and cyto-
megalovirus [26,27]. Most recently our Hannover group
[28] examined liver biopsies in 74 infants with BA against
a panel of possible hepatotropic viruses and showed that
viral RNA/DNA could be found in just less than half
(REOvirus 33%; cytomegalovirus 11%; adenovirus 1% and
enterovirus 1.5%). The debate revolves around whether
these are simply (not so) innocent bystanders or integral
to the cholangiodestructive mechanism. The faecal flora of
infants with BA is different [29] and enteric absence of bile
salts may allow selection of such enteroviruses. Does it
make a difference? In the follow-up to the German study
there was no difference in outcome between virus + ve
and virus–ve infants[30]. However, in a separate study
using only infants who tested IgM+ ve for CMV (n = 20)
from our London group compared to 111 infants with
negative IgM serology we have shown reduced clearance
of jaundice and a significantly increased mortality in the
CMV IgM+ ve group [31].
Cellular kinetics, inflammation and clinical biliary atresia
There is a potent inflammatory reaction in the livers of
infants with isolated BA, focused on the portal tracts
[32-34]. There is abnormal expression of MHC Class II
antigens and the adhesion molecules ICAM and VCAM
on both vascular and biliary endothelium, together with
a sometimes dense population of activated and prolifer-
ating mononuclear cells [35], [36]. Among these are
mast cells [37] and Kupffer cells [38] but they seem to
be predominantly CD4+ T cells and NK cells [39,40]
orchestrating a Th1 cytokine response [41,42] with in-
creased expression of IL-2, IFNγ, TNFα and IL-12 and
other proinflammatory factors, e.g. iNOS and NO
[43,44]. The cell lines appear to be oligoclonal at least in
the CD4+ and CD8+ subsets identified by Mack et al.
[45]. Alternatively, Shinkai et al. observed a predomin-
antly CD8+ infiltrate in their infants with BA [46,47]
though their study group was much smaller; and previ-
ous work has suggested poor CD8+ cytotoxic function
[48]. Muraji et al. has also described significantly more
CD8+ T cells in the livers of BA infants, and interest-
ingly, these appear to be of maternal origin [49]. This is
the interesting concept of maternal microchimerism,
whereby transplacental passage of immune active cells
(seemingly CD8+ CD45+) occurs, localizing within the
liver and initiating a form of graft-versus-host reaction.
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target for an autoimmune response. Finally, a third sub-
set of helper T cells, Th17+ cells also seem to play a sig-
nificant role in mucosal host defence and have been
implicated in some autoimmune cholangiopathies such
as primary biliary cirrhosis in adults. Such Th17+ cells,
can be shown to accumulate at the bile duct epithelial
interface and infiltration of this subset in portal tracts
and also appears to be a characteristic of BA [50,51].
There is also a pronounced soluble inflammatory com-
ponent observable at the time of presentation. Initially
this with increased levels of sICAM and sVCAM [52,53]
and the cytokines IL-2 and Il-10 compared to controls
which then actually increases following the KPE. In the
case of IL2, IL-18 and TNFα this increase is very marked
to about 9-12 months. If there has then been resolution
of jaundice then it tends to abate but only sICAM
appears to be closely correlated with plasma bilirubin
levels [54].
Early-onset of liver fibrosis appears to be a defining
characteristic of BA, perhaps not seen in other chole-
static conditions of infancy such as Alagille’s syndrome
or α-1-antitrypsin deficiency. Harada et al. cultured
human intrahepatic biliary epithelial cells (BECs) and
showed that exposure to a viral RNA analogue triggered
an immune reaction which persisted long after removal
of the virus [55]. Excessive activation of Hedgehog (Hh)
signaling pathways and increased expression of matrix
metalloproteinases (MMP) [56] can be shown in BA in-
fants promoting epithelial–to–mesenchymal transition
of BECs and leading to enhanced hepatic fibrogenesis.
Resident (Kupffer cells) or systemic / recruited macro-
phages /monocytes seem to play a dual role in this
process. Initially they may act as antigen presenting cells
(APCs) early on in the process but they also appear
to be the key factor in this development of fibrosis.
Tracy et al. in 1996 first highlighted the increase in the
resident macrophage population in BA and increased
levels of both CD68+ cells and its circulating markers
(TNFα and IL-18) have been shown [57,58].
Biliary atresia in the animal world
The lamprey is an eel like creature which parasitizes and
feeds on the blood of fish and is unique amongst verte-
brates in that its liver does not have a gallbladder, biliary
tree or even canaliculi. It does have them in the larval
stage but then they disappear on metamorphosis to the
adult stage. The only real effect on their hepatocytes
appears to be increased numbers of cytoplasmic vacu-
oles presumably where some form of bile degradation
occurs [59,60]. However, despite a series of papers,
which looked at the lamprey as a potential animal model
for the congenital form of BA, this direction is no longer
pursued.There have been sporadic reports in the veterinary lit-
erature of biliary atresia or at least BA-like lesions in
lambs, foals, dogs, calves and even a Rhesus monkey
(associated with REOvirus) [61,62]. An amazing epi-
demic of BA in over 200 lambs and 9 calves was attrib-
uted to maternal grazing and ingestion of a toxic weed
known as the red crumbweed (Dysphania glomulifera
subsp. glomulifera) growing on the newly exposed silt
foreshores of Burrinjuck Dam, New South Wales,
Australia [63].Biliary atresia in the laboratory
Bile duct development
There is much ignorance about the steps of bile duct de-
velopment during the embryonic period, and what is
known has been largely derived from work in mice and
zebrafish [64] and is somewhat outside the remit of this
review. The “ductal plate” refers to differentiation of
hepatoblasts into BECs and then condensation around
in-growing portal venules starting at the porta hepatis
and occurs at around 8-10 weeks with later remodeling
and definitive tubularisation via selection and deletion.
This appears to be induced in the fetal liver by a
periportal gradient of activin/transforming growth
factor-beta (TGFβ) signaling. The current consensus is
that the entire intrahepatic system is derived from this
mechanism as suggested by Desmet [65]. The establishment
of biliary continuity with the lumen of an already
established foregut diverticulular structure occurs although
when and how is indistinct. The hepatocytes start to secrete
bile from about the 12th week.
Cholangiocyte specification is promoted by the Wnt/
β-catenin signaling pathway and initiation and overall
control appears to be a function of the Notch signaling
pathway, Notch 2 rather more so than Notch 1 [66,67].
Certainly, mutations in the latter’s ligand (Jagged1) ap-
pear responsible for bile duct hypoplasia of Alagille’s
syndrome (and murine equivalents). Various transcrip-
tion factors (e.g. Hes-1, Hnf-6, Foxa1/2, TGF-β) are also
involved in remodeling of the ductal plate and preven-
tion of excess cholangiocyte proliferation.
Inversin (Inv) is a gene localised to Ch 4 in humans. The
inv mutant mouse, created by insertional mutagenesis,
was first reported in 1993 by Yokoyama et al. [68], who
described situs inversus and severe jaundice in homozy-
gous mutants. The actual biliary pathology has been dis-
puted however, with Mazziotti et al. [69] suggesting
extrahepatic discontinuity but more recently Shimadera
et al. [70] showing periportal ductular proliferation (per-
haps akin to ductal plate malformation) and anomalous
development of the intrahepatic bile ducts but a normal
extrahepatic system. Neither group demonstrated inflam-
matory, ischemic or cystic features.
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Ligation of the common bile duct in fetal lambs at about
80 days of gestation produces cholestasis and cystic
change in the bile duct evident at birth and, perhaps, re-
sembling those infants with CBA [71,72]. Similar findings
can be shown in fetal rabbits when the hepatic artery has
been ligated and in one study absence or hypoplasia of the
intrahepatic bile ducts was also seen in 5 out of 14 five-
week old pups [73].
The effect of drugs administered during pregnancy has
also been studied. Hosada et al. administered intraperi-
toneal phalloidin, an actin-binding toxin derived from
the Death Cap mushroom (Amanita phalloides) to
Wistar rats on gestational day 15. After birth, the pups
presented with cholestasis and an increased volume of
actin filaments around bile ducts, but without typical BA
features [74]. In another study, the anti-helminthic drug,
1,4-phenylenediisothiocyanate, was given orally to preg-
nant, newborn and adult Wistar rats. Peribiliary inflam-
mation and dilatation was found in the post-natal drug
groups but the most convincing BA-like findings with
almost complete obliteration but no dilatation was found
in those exposed to the drug during the fetal period and
at one month after birth [75].
Inducing cholestasis and atresia in postnatal experiments
A number of manoeuvres, e.g. ligation of common bile
duct, intrabiliary injection of sclerosants and superglue, in a
variety of animal models, e.g. mice [76], rat [77], and
minipigs [78], have been reported with the intention of re-
producing early neonatal cholestasis. These studies seem to
have more value in replicating the metabolic consequences
of cholestasis in this age-group rather than providing a real
insight into aetiology. One exception may be that of
Schmeling et al. [79], who infused phorbol myristate acetate
(PMA) into the gallbladders of golden hamsters. PMA is
not in itself toxic but it does activate peribiliary neutrophils
which release potent free-radical oxygen species thereby
setting up a marked peribiliary inflammatory process and
ultimately fibrosis. Actual obliteration and the effects on
the extrahepatic biliary tree were not commented upon.
A possible immune-mediated mechanism was first
investigated by Schreiber et al. in 1992 [80]. They
transplanted fetal, neonatal and adult bile ducts taken
from C57BL/6 into the adult B10 mice and observed a
dynamic pattern of rejection and fibrosis. They found
that prenatally harvested bile ducts were relatively
“immunoprivileged” because of diminished expression of
HLA class I and II antigens and that in adult mice, graft
rejection could be stopped by cyclosporin A.
The viral model of biliary atresia
Initial mice models used intraperitonal inoculation of
REOviruses with varying serotypes, e.g. type 3 (Abney)[81,82]. All seemed to induce liver and biliary inflamma-
tion with jaundice as a consequence, but without real
features of atresia.
Oral administration of REOvirus to newborn ND4
Swiss Webster mice showed that hepatotropism was
higher in those strains which have the capacity to bind
sialic acid as a co-receptor. These mice presented with
oily fur syndrome, portal lymphoid infiltrates in the liver
and sporadic bile duct necrosis. However, mortality
appeared to be due to encephalitic disease, and surviving
pups recovered completely from their hepatobiliary
pathology [83]. Similar observations were made when
other hepatotropic Rotavirus and REOvirus strains were
used [84,85].
A better model with peribiliary inflammation leading
to features of actual irreversible extrahepatic atresia
was developed by infecting newborn Balb/c-mice with
Rhesus Rotavirus (RRV) [86]. In the initial study [87]
about half of the orally RRV infected pups developed
cholestasis, and most died within 3 weeks. Dissection
showed obstruction of the common bile duct and BA-
like changes in the liver, e.g. inflammatory infiltrates and
bile duct proliferation. Our Hannover group modified
this model using intraperitoneal RRV given at 24-48
hours with an increase in the proportion becoming cho-
lestatic and the development of atresia-like biliary seg-
ments (Figure 2) [88-90]. Still, older 3 week old pups
failed to show much in the way of liver fibrosis, and
using picosirius red staining collagen deposition around
portal triads was much less obvious than in the human
condition [91,92].
To work, however, three preconditions must be ful-
filled; but it offers a way of understanding a mechanism
for the observable pathology. The preconditions are such
that the strain of mouse, the timing and the dose of
virus inoculation must be perfect to achieve BA-like
pathology [89,93,94]. Maternal infection during late
pregnancy does not induce jaundice, but does prevent
the offspring from developing cholestasis following post-
natal RRV application [95,96]. Post-natal inoculation at
12-24 hours after birth produces BA-like lesions in over
90% of animals compared to less than 20% if the inocu-
lation is given at 48-72 hours. Table 1 illustrates this
effect of mouse strain time of virus administration and
viral load on outcome, and shows that too high a dose is
lethal before the onset of biliary pathology. On the other
hand, changing of the RRV-dosage or the mouse strains,
respectively, does not necessarily prevent infected pups
from cholestasis, but from developing destruction and
atresia of extrahepatic bile ducts. Those mice mostly
catch up weight and recover completely. The versatility
of the model is also limited as sequential investigations
cannot be performed in the same animal. Diseased pups
are extremely unstable and too small for repetitive
Figure 2 The Rhesus Rotavirus induced biliary atresia model in newborn Balb/c-mice. (A) Two 14 day old Balb/c mice, left, healthy control,
right, jauniced with oily fur syndrome. (B) inflammatory infiltration in a portal field (9 day old, H x E 400×). (C) Section of the hepatoduodenal
ligament at the level of the common bile duct atresia (16 day old, H x E 250×) (59). (D) Scanning electron microscopy of a whole specimen,
showing a small gallbladder, a vanishing common bile duct along with the hepatoduodenal ligament a prestenotic cystic dilatation near to the
duodenum (15 day old) (56).
Table 1 The incidence of virally induced cholestasis and
biliary atresia depends on three variable parameters,
mouse strain, time (hours post partum) and dosage of
Rhesus rotavirus application
Variable parameter Cholestasis Biliary atresia
Mouse strain
Balb/c 55, 71 67%-85% 67%-91%
CD 59 33% 46%
NMRI 59 19% 50%
C57Bl6 67 13% 100%
Balb/c-IFN-γ–/–65 90%-100% 20%
Balb/c-TNF-α–/–68 No data 86%
Balb/c-Mx + −A2G 71 65% 65%
WT 129 70 30% 50%
A 129 IFN-α/β receptor–/–70 79% 96%
G 129 IFN-γ receptor–/–70 39% 86%
AG 129 IFN-α/β/ γ receptor–/–70 70% 96%
Age at infection
12-24 hours 65, 83 80%-86% 90%-100%
24-48 hours 55 61%-85% 69%-91%
48-72 hours 52, 53 13%-42% 0-17%
Infective dose
107* pfu 62 100% 100%
106 pfu 62 86% 100%
105 pfu 62 38% 100%
104 pfu 62 0 0
pfu–plaque forming unit.
* >106 pfu is not recommended, because the early lethality is inacceptably high.
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the assumed immune cascade can be studied by extrac-
tion of cell lines, e.g. cholangiocytes taken from RRV
infected pups can be isolated [97-99]. One advantage of
this model is that modification of each of the precondi-
tions allows investigation of subsequent immunological
or cellular changes.
The dynamic pattern of RRV infection can be moni-
tored on the basis of the expression of mRNA encoding
RRV non-structural and structural proteins, e. g. VP6,
VP4, and viral plaque assays. So, the peak of viral load is
seen at day 7 after inoculation, and is mostly cleared
from the liver by day 14 [97-99]. However, the cellular
and humoral immune response persists even after
complete viral clearance.
The steps of the immune reaction to RRV inoculation
appear to be as follows (Figure 3). The viruses target
cholangiocytes and macrophages [100], while the initial
response depends upon innate NK cells and APCs indu-
cing a T-cell mediated immune response. In this murine
model, cholangiocytes and dendritic cells [86], appear to
act as the APCs via expression of both MHC class I anti-
gens [97,98,101] (to cytotoxic CD8+ cells) and MHC
class II antigens (to CD4+ T-helper cells). Activated
CD4+ cells, driven by IL-12, produce a bewildering range
of cytokines, such as IL-2, IFN-γ, IFN-α, IFN-β, CXCL 9,
CXCL 10, CCL2, CCL5, Stat 1, Granzyme A and B,
Osteopontin, etc. [102,103]. Lack of IL-12 does not seem
to abolish this particular response, as Th1 dependent cy-
tokines, such as IFN-γ and TNF-α, are not reduced in
IL-12 deficient mice, suggesting the presence of
Figure 3 Schematic network of cellular dynamics and immunological cascade in mouse model of biliary atresia. For more details see
Table 2.
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has been shown to induce epithelial injury and inflam-
matory obstruction of extrahepatic bile ducts in the
same mouse model [106]. Cholestasis becomes evident
one week after infection and the infiltration of CD4+ and
CD8+ cells increased three-fold with a peak on day 14.
Interferons seem to play a crucial role in this model, as
Mx protein (an IFN type I specific indicator) persists in
hepatocytes, bile ducts and intrahepatic endothelial cells
of cholestatic mice beyond the second week after RRV in-
fection [107,108]. In other studies, for instance with IFN-
receptor knock-out mice, it can be shown that IFN type II
attenuates the tropism of lymphocytes to bile ducts and is
somehow imperative to the development of BA [99,109].
Depletion of CD8+ cells, as well as loss of IFN-γ, re-
duces the incidence of experimental BA. IFN-type II reg-
ulated chemokines such as Mig, IP-10 and I-Tac can be
shown to peak at day 7 only in BA-developing Balb/c
but not in IFN-γ–/–mice [110]. Thus in these knock-out
mice, early lobular and portal inflammation with
periductal infiltration by neutrophils is still seen at day 3
and is followed by bile duct proliferation. But in con-
trast, they did not go on to develop bile duct obstruction
or atresia and indeed recovered in most cases. Adminis-
tration of recombinant IFN-γ restores this detrimental
consequence. We hypothesis that both IFN-γ and CD8–
T cells constitute two complementary mechanisms in
which IFN-γ and other Th-1 dependent cytokines serves
as a molecular signal that promotes the infiltration of in-
jured bile ducts by inflammatory cells, while CD8- T
cells, together with NK-cells, trigger the transformation
of an ongoing inflammatory process into fibrosis and
occlusion of the bile ducts [111,112].The role of CD19+ B-cells and activation of Th2
effector cells remains unclear and the expression of Th2
related cytokines such as IL-4 and IL-5 has not been
uniform [99,113].
Regulatory T-cells (T-reg) seem to be involved in this
auto-immune process. In mice, T-regs are absent in the
newborn and become activated during the first week of
life. Initially substitution of T-regs in the mouse model
was supposed to reduce the incidence of BA and shift
the focus onto NK-cells [114,115]. Adoptive transfer of
T-cells from mice with RRV-induced BA to SCID recipi-
ents results in periductular inflammation, and a bile duct
epithelia specific T-cell mediated autoimmunity [116].
The hypothesis that humoral autoimmunity plays some
role in the pathology of BA [117] has been endorsed by
detection of anti-α-enolase autoantibodies in both ex-
perimental and human BA and found in patients with
typical autoimmune liver disease, such as autoimmune
hepatitis and primary sclerosing cholangitis.
Apoptosis of the biliary epithelium (as shown by
TUNEL assay and expression of caspase 1 and 4) and
activation of the complement cascade appears to peak at
day 7 and can be induced by proinflammatory cytokines
such as TNF-α and IFN-γ [109]. Additionally, NF-κB,
which is a first responder to harmful cellular stimuli as a
rapid-acting primary transcription factor inducing apop-
tosis, shows an increasing level from day 5 with a peak
at day 15 [84,118]. It still remains unclear if apoptosis is
part of the clearing mechanism after viral infection or a
hyper-responsiveness consistent with immature immun-
ity [119].
There have also been attempts to modify pathology
using this model. For instance, repeated administration







T-regs [123] Circulating and local T-regs in lymph nodes of
the porta hepatis are reduced in CMV positive
patients with BA, compared to age matched controls
with other cholestatic liver diseases
CD4 + −T-Cells Osteopontin [43] [124] Osteopontin mRNA expression was shown in liver
biopsies of BA patients and also in experimental BA
Cholangiocytes TLRs [125] TLRs 2 and 8 mRNA expression was higher in early states
of BA-patients and significantly elevated to age matched controls
CD4 + −T-Cells Th2/IL-13 [106] [106] STAT1–/–mice infected with RRV exhibit a Th2 dominated inflammation,
evidence can be found in humans, too, also mediating experimental
biliary atresia if not accompanied by IL-13 blockade
CD4 + −T-Cells [41] DNA-Hypomethylation throughout the genome of
CD4 + −T-Cells is negatively correlated with IFN-ɣ
mRNA-levels compared to healthy controls
Dendritic Cells [86] [86] RRV-primed DC, also present in human livers, boost lymphocyte
expansion and mediate epithelial injury whereas
depletion of DC or blocking IL-15 reduced NK-Cell activation
Macrophages Mip2/Cxcl2 [100] RRV-infected Macrophages influence neutrophil chemotaxis
iNOS [44] Liver samples show a strong correlation between
NF-κB -activation and iNOS hyperexpression
T-regs [114,126] Activated T-regs reduce inflammatory cytokine production
and suppress NK-cell activation in vitro and in vivo
Cholangiocytes [101] Release of CXC–and CC-Chemokines by cholangiocytes
markedly increase upon onset of disease
Cholangiocytes [97] In the setting of RRV-infection and Th1 inflammation
cholangiocytes produce inflammatory cytokines and
chemokines but do not function as APC despite
expressing all necessary surface markers
NK-Cells [127] [115] NK-Cells populate the liver of mice, and humans, and
their depletion or blocking Nkg2d prevents
cholangiocyte lysis in vitro and in vivo
IFN-ɣ /TNF-α [109] Inhibition of caspases reduces apoptosis induced
by synergism of IFN-ɣ and TNF- α
CD8 + −T-Cells [49] Primarily CD8 + −T-Cells of the lymphocyte
infiltrate suffer from maternal micochimerism
NF-κB gene
products
[55] Intrahepatic Biliary Epithelium reacts with NF-κB
activation if treated with a viral-dsRNA-analogon
TNF-α [103] Although highly elevated in experimental biliary
atresia blocking TNF- α exerts no effect
T-Cells [45] CD4+ and CD8 + −T-Cells show oligoclonal expansion
of TCR Vβ with Vβ20 dominating in the latter
NF-κB gene
products
[117] Biliary Epithelium reacts similar to a viral infection
if treated with a viral-dsRNA-analogon
CD8 + −T-Cells [110] Depletion of RRV-primed CD8 + −T-Cells reduces
disease incidence and mediate the epithelial injury
IL-12 [105] Loss of IL-12 in mice does not prevent experimental
biliary atresia but shifts the Th1-phenotype of
inflammation towards neutrophils
CD4 + −T-Cells IFN-ɣ [116] Although not being able to elicit experimental biliary atresia
in SCID mice RRV-primed CD4 + −T-Cells are the source of IFN-ɣ
IFN-ɣ [107] IFN-ɣ-RII is without influence on development
of experimental biliary atresia
CD8 + −T-Cells [46] Elevated numbers of CD8 + −T-Cells populate
the portal tract in biliary atresia
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Table 2 All papers, which have so far been published concerning BA and immunology in both, human and
experimental BA (Continued)
T-Cells [47] T-Cells within the livers of diseased express more CXCR3 than controls
IFN-ɣ [128] RRV-challenge of mice upregulates Interferoninducers followed by the IFN-ɣ
network genes with onset of disease in the biliary transcriptome
CD4 + −T-Cells
Macrophages
Th1 TNF-α [113] With RRV present one week p.i. the portal tract infiltrate is predominated
by CD4 + −T-Cells producing IFN-ɣ and Macrophages producing
TNF-α, whereas both effectors produce TNF-α after virus clearance
Macrophages [129] Increased infiltration of Macrophages in the liver after
Kasai is associated with a favourable outcome
IFN-ɣ [99] IFN-ɣ depletion prevents bile duct obstruction while administering
IFN-ɣ to IFN-ɣ–/–induces experimental biliary atresia after RRV-injection
CD4 + −T-Cells Th1 [33] The portal tract inflammatory response is dominated by CD4 + −T-Cells
with a Th1-cytokine response and an increased number of Kupffer cells
CD4 + −T-Cells [130] The reduced number of naïve-CD4 + −T-Cells in
patients persists after transplantation
Costimulatory
factors
[35] Costimulatory factors of APC are highy expressed on bile duct epithelium
Lymphocytes [36] Leukocyte infiltration of livers often do not
include immunocompetent lymphocytes
Th1 [43] Within the transcriptome of pooled mRNA genes
pointing towards a Th1-profile are often upregulated
Lymphocytes [40] Activated and proliferating lymphocytes populate the liver
CD8 + −T-Cells [48] CD8+ T-Cell infiltrate of the proliferating bile ducts after
Kasai operation lack the phenotype of activated cytoxic lymphocytes
CD4 + −T-Cells [42] A decreased number of naïve-CD4 + −T-Cells is accompanied
by reduced receptor density
Mast cells [37] The number of intrahepatic mast cells negatively correlates with liver function
Macrophages IL-18 [38] Proliferation of Kupffer-Cells is found in the liver
accompanied of elevated IL-18 levels in serum
IFN-α [121] IFN-α prevents experimental biliary atresia
Macrophages [58] Increased infiltration of Macrophages in the liver after
Kasai is correlated with a bad prognosis
Macrophages [57] Macrophages coexpress CD68 and CD14 in biliary atresia
Lymphocytes [34] Lymphocyte infiltration into biliary epithelium is quite similar to GVHD
Mononuclear
cells
[131] Mononuclear infiltrate in BA is more similar to normal
livers than to those suffering from chronic infection or autoimmunity
T-regs [114,126,132] The RRV-induced murine model of BA is associated with
defects in the production and function of T-regs, probably suppressing
DC-dependent activation of naive NK cells
References are listed in reverse chronological order and the key message of each paper is summed up as well as the key effector cells and/or
corresponding cytokines.
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orate the development of BA-like lesions and increase
survival. It remains unclear if this boosts viral clearance
or modulates the immune response [120,121]. Immun-
isation of dams with RRV before mating and during
pregnancy protects their offspring from cholestasis
and development of BA [95,96]. Dams, which were
preconceptionally and orally vaccinated with commer-
cially available rotavirus vaccines, did not prevent their
RRV infected newborns from becoming jaundiced, but
did prevent the development of BA [122]. While these
preliminary results are far from clinical application inhumans, the potential for at least some form of prophy-
laxis has been shown.
Table 2 illustrates a chronological overview of the key
immunological observations mentioned in the text in
both human and experimental BA to date.
The key question, of course, is does this experimental
model of BA in mice really mirror the human disease
and can the putative mechanism really be applied out-
side of the mouse [16,41]? One problem is that chole-
static pups do not survive longer than 21 days. About
80% of the RRV infected newborn mice develop jaundice
by the 7th day, stop gaining weight and die within three
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death is still unclear, in as much as these mice no longer
have the virus. It is likely that dams no longer feed their
diseased pups and one task would be to improve the sur-
vival of diseased pups, perhaps by means of artificial
nourishment, in order to simulate better the natural his-
tory of BA. One final fundamental dissimilarity between
murine and human BA is that mice do not develop se-
vere liver fibrosis.
Optimizing the infective mouse model is a promising
outlook for understanding of the pathological mechan-
ism in mice but it needs to be balanced by effective
translational research. We first see infants with BA when
a good deal of the damage has already been done and do
not know whether their immune response is primary
and etiological or simply a secondary phenomenon.
Conclusion
Donald Rumsfeld served as the American secretary of
state for defense from 2001-6 and highlighted rather a
neat philosophical principle, although it was widely de-
rided at the time. He said: “There are known knowns.
These are things we know that we know. There are
known unknowns. That is to say, there are things that
we know we don’t know. But there are also unknown
unknowns. There are things we don’t know we don’t
know.” In terms of BA what do we know? We know it is
an exceptionally rare disease and its onset is confined to
the newborn period. We know that there are distinct
clinical variants and therefore more than one mechan-
ism for obliteration. Primary failure to develop luminal
continuity seems obvious for “genetic” conditions such
as BASM and similarly some local fetal insult or event
perhaps causes CBA. What little clinical evidence there
is suggests that most of the remainder are cholestatic in
the first week of life. What are the known unknowns
then? We struggle to relate what the best available ex-
perimental model tells us about the pathological mech-
anism evident in the human condition with any degree
of consistency or accuracy [40,45,54]. That there is an
integrated, multilayered, harmonised and structured in-
exorable inflammatory response to something (possibly
viral) is clear, and that it occurs crucially within a very
narrow window just after birth also appears obvious
from the mouse model. The response is aberrant and
peculiar to this period and may be auto-immune in its
effect–although there is no suggestion that it continues
much beyond the first few months (otherwise KPE and
transplanted livers would invariably fail) or has any
effect on other organs. Something makes the immature
biliary tract susceptible in a way that the older child’s or
adult’s liver is not. But viruses are ubiquitous, and it
seems that many disparate viruses fit the offender profile
laid out by the experimentalists; and if their role iscrucial rather than incidental then why is this disease so
rare? Improved synchronicity between those model-
based workers with those able to furnish clinical material
would help resolve some of these known unknowns.
What then of those unknown unknowns, well we shall
have to wait and see as they will surely declare them-
selves to a future audience.
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